• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Cochrane Review: Oxytocin to Prevent Postpartum Hemorrhage in Third Stage of Labor

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Active management of third stage
    • Prophylactic uterotonic | Early umbilical cord clamping | Controlled cord traction
  • Uterotonic choice varies
  • Salati et al (Cochrane Reviews, 2019) sought to determine the effectiveness of oxytocin to prevent PPH and other morbidities

METHODS:

  • Systematic review
    • Searched: Cochrane Pregnancy and Childbirth’s Trials Register, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform (ICTRP) and reference lists of retrieved studies
  • Inclusion criteria
    • Randomized, quasi-, or cluster-randomized trials that included women undergoing vaginal delivery who received prophylactic oxytocin during the third stage of labor
  • Primary outcome
    • Blood loss ≥500 mL after delivery
    • Need for additional uterotonics
    • Maternal all-cause mortality
  • Data analysis
    • Two authors independently determined trials for inclusion, compiled data, and assessed trial quality
    • The quality of evidence was assessed using the GRADE criteria

RESULTS:

  • 23 trials | 10,018 women
    • Quality of evidence ranged from very low to moderate

Prophylactic oxytocin versus no uterotonics or placebo (9 trials)

  • Compared to placebo or no uterotonic, prophylactic oxytocin may reduce risk of
    • Blood loss ≥500 mL after delivery: Risk ratio (RR) 0.51 (95% CI, 0.37 to 0.72; low-quality evidence)
    • Blood loss ≥1000 mL after delivery: RR 0.59 (95% CI, 0.42 to 0.83; low-quality evidence)
    • Need for additional uterotonics: RR 0.54 (95% CI, 0.36 to 0.80; moderate-quality evidence)
  • No significant difference in transfusion risk
    • RR 0.88 (95% CI 0.44 to 1.78; low-quality evidence)

Prophylactic oxytocin versus ergot alkaloids (15 trials)

  • Compared to ergot alkaloids, it is uncertain whether oxytocin reduces the likelihood of
    • Blood loss ≥500 mL: RR 0.84 (95% CI, 0.56 to 1.25; very low-quality evidence)
    • Blood loss ≥1000 mL: RR 1.13 (95% CI, 0.63 to 2.01; very low-quality evidence)
    • Need for additional uterotonics: RR 0.89 (95% CI, 0.43 to 1.81; very low-quality evidence)
    • Need for blood transfusion: RR 1.37, 95% CI 0.34 to 5.51; very low-quality evidence)
  • Oxytocin probably increases the risk of a prolonged third stage >30 minutes
    • RR 4.69 (95% CI, 1.63 to 13.45; moderate-quality evidence)
  • Oxytocin is probably associated with a lower risk of vomiting
    • RR 0.09, 95% CI, 0.05 to 0.14; moderate-quality evidence)
  • Oxytocin’s impact on headaches is uncertain
    • RR 0.19 (95% CI, 0.03 to 1.02; very low-quality evidence)

Prophylactic oxytocin/ ergometrine versus ergot alkaloids (4 trials)

  • Compared to ergot alkaloids, oxytocin-ergometrine may slightly reduce the risk of blood loss ≥500 mL after delivery
    • RR 0.44 (95% CI, 0.20 to 0.94; low-quality evidence)
  • Note: No subgroup differences were observed between active or expectant management, or different routes or doses of oxytocin for any comparisons

CONCLUSION:

  • Based on the above results, the authors conclude

Oxytocin may reduce blood loss and the need for additional uterotonics when given prophylactically in the third stage of labour, and therefore could be considered as a component of active management of the third stage of labour

  • Oxytocin may have less side effects than ergot alkaloids but possibly associated with an increased risk of third stage >30 minutes
  • Well-designed RCTs will be required to compare ergot alkaloids and oxytocin

Learn More – Primary Sources:

Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Learn More  »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Postpartum Hemorrhage – Medications to Treat Uterine Atony 
Postpartum Hemorrhage Prophylaxis: The World Health Organization Recommendations
How Effective is Intrauterine Balloon Tamponade for Severe Postpartum Hemorrhage
Heat Stable Carbetocin: A Heat-Stable Alternative to Oxytocin?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site